NGKSY vs SYRE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NGKSY · Niterra (ADR)$7.59 ▲ 7.63%
SYRE · Spyre Therapeutics$103.86 ▲ 7.53%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NGKSY +28.5%
- SYRE +368.3%
Head to head
| Metric | NGKSY | SYRE |
|---|---|---|
| Price | $7.59 | $103.86 |
| Change today | ▲ 7.63% | ▲ 7.53% |
| Market cap | $9.87B | $9.86B |
| Return, 3 months | -23.7% | -1.4% |
| Return, year to date | +8.1% | +217.0% |
| Return, 1 year | +28.5% | +361.2% |
| P/E (TTM) | 8.3 | – |
| P/B | 1.7 | 10.9 |
| P/E percentile vs own 5y | – | 2nd |
| Dividend yield | 2.84% | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | +1.4% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | -28.5% |
| Analyst target vs. price | – | +17.5% |
| Analyst buy share | – | 100% |
| RSI (14) | 49 | 65 |
| 30-day volatility | 78.1% | 70.7% |
| Max drawdown, 1 year | -38.9% | -27.8% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NGKSY is the largest of the group by market value.
- SYRE has returned the most over the past year.
- SYRE has been the calmest stock over the last 30 days.